Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital

Edesa Biotech, Inc.

Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.
Cash and equivalents $1.0M at Sep 30; negative working capital of $0.2M.
Post-year end: $1.5M from CEO-affiliated entity + $0.6M net from ATM offering.
Pivoted EB05 (paridiprubart) to U.S. govt-funded ARDS study; plans EB06 IND submission.
Topline Phase 2 EB06 results expected 12-18 months after FDA clearance; funded subject to capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.